Universal Beteiligungs und Servicegesellschaft mbH Takes $3.63 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 23,197 shares of the company's stock, valued at approximately $3,634,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of Krystal Biotech as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in KRYS. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech in the 4th quarter worth approximately $95,000. Covestor Ltd boosted its position in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. KBC Group NV boosted its position in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Up 0.4%

Shares of NASDAQ:KRYS traded up $0.59 on Thursday, reaching $132.62. The company had a trading volume of 233,046 shares, compared to its average volume of 311,324. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The firm's 50 day simple moving average is $151.55 and its 200-day simple moving average is $163.81. The firm has a market capitalization of $3.83 billion, a PE ratio of 44.35 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KRYS. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 6th. Chardan Capital restated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $211.13.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).